Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
ViroMissile, Inc.
Dana-Farber Cancer Institute
University of Florida
Essen Biotech
Angiex, Inc.
Tanabe Pharma America, Inc.
M.D. Anderson Cancer Center
Pfizer
Hangzhou DAC Biotechnology Co., Ltd.
Washington University School of Medicine
3B Pharmaceuticals GmbH
Fudan University
Jonsson Comprehensive Cancer Center
Eli Lilly and Company
NextPoint Therapeutics, Inc.
Chinese University of Hong Kong
Elevation Oncology
Cedars-Sinai Medical Center
Agenus Inc.
Rutgers, The State University of New Jersey
Cedars-Sinai Medical Center
TransThera Sciences (Nanjing), Inc.
OHSU Knight Cancer Institute
Charite University, Berlin, Germany
Prelude Therapeutics
M.D. Anderson Cancer Center
pharmaand GmbH
Kineta Inc.
Eastern Cooperative Oncology Group
Quadriga Biosciences, Inc.
Ludwig Institute for Cancer Research
Ludwig Institute for Cancer Research
MacroGenics
Case Comprehensive Cancer Center
Celgene
InSightec
InSightec
Tel-Aviv Sourasky Medical Center
OPKO Health, Inc.
CytoMed Therapeutics Pte Ltd
InSightec
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pfizer
University Health Network, Toronto
Corcept Therapeutics
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Altor BioScience
Alliance for Clinical Trials in Oncology